A LANDMARK STUDY. TO ESTABLISH A NEW STANDARD OF CARE.

FOR SELECT HEART FAILURE PATIENTS WITH CLINICALLY SEVERE SECONDARY MITRAL REGURGITATION.

The first and only mitral intervention shown to improve the prognosis of patients with heart failure by reducing secondary mitral regurgitation due to left ventricular dysfunction.

MitraClip® has shown a 47% relative risk reduction in heart failure hospitalizations and a 38% relative risk reduction in mortality through two years. Patients who were treated with MitraClip had significant improvements in quality-of-life and functional capacity during 24-month follow-up compared to guideline directed medical therapy.

Landmark Trial

COAPT TRIAL RESULTS SUMMARY

REDUCES HOSPITALIZATIONS
47%
RELATIVE RISK REDUCTION IN HEART FAILURE HOSPITALIZATIONS
Treatment with MitraClip plus medical therapy was associated with a statistically significant reduction in heart failure hospitalization through two years compared to medical therapy alone (67.9 percent vs. 35.8 percent; p<0.001).
IMPROVES SURVIVAL
38%
RELATIVE RISK REDUCTION IN MORTALITY
MitraClip treatment was superior in reducing all-cause mortality through two years, from 46.1 percent of patients in the control group to 29.1 percent in the device group (p<0.001).
FEEL BETTER
72%
OF PATIENTS IN NYHA CLASS AT I/II
72% of MitraClip patients had NYHA Class at I/II at 12 months. 50% of the control patients had NYHA Class I/II at 12 months with 22% difference between arms.
MitraClip® is not approved by the FDA for secondary MR and is currently under investigation in the U.S. for secondary MR. The device has been approved to treat primary MR in the U.S. since 2013 and CE marked since 2008 for primary and secondary MR. Please check with your Abbott representative or physician for local approval status.

LEARN MORE ABOUT MITRAL REGURGITATION:

If you are a patient or a family member of a patient, talk to your physician to learn more about Heart Failure and Secondary MR or visit www.MitraClip.com.

MitraClip® is not approved by the FDA for secondary MR and is currently under investigation in the U.S. for secondary MR. The device has been approved to treat primary MR in the U.S. since 2013 and CE marked since 2008 for primary and secondary MR. Please check with your Abbott representative or physician for local approval status.